FDA puts Hemopure trial on hold as it reviews safety

The FDA has put a clinical trial for Biopure's Hemopure therapy on hold saying it needs answers to several safety questions. The Navy has joined with Biopure to seek approval for a trial of the cow-blood derivative on trauma patients outside of hospitals. Researchers want to test Hemopure in a mid- to late-stage trial that would test the safety and effectiveness of the therapy on patients suffering acute blood loss. The blood derivative is designed to be stored at room temperature and remain viable for years.

- read this AP report for more